Effect of Methylcellulose or Psyllium on Fermentation of inUlin Assessed USing MRI

NCT ID: NCT06291272

Last Updated: 2024-08-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-15
• Study Completion Date: 2024-06-30

Brief Summary

The challenge is to understand how fibre interacts with whole-gut function to alter colonic fermentation of fermentable oligo-di- and mono-saccharides and polyhydric alcohols (FODMAPs). Studies will exploit the recent availability of a range of food grade modified celluloses which can form gels at body temperature to perform human studies to explore whether the beneficial effect of psyllium is unique or will be found with all gelling substances (4). The investigators are currently performing the COCOA2 study (Effect of modified cellulose on colonic fermentation of inulin) using a modified methylcellulose (results awaited). The investigators now wish to image what happens in the colon when methylcellulose is ingested to enable planning of the next step in the research programme.

Detailed Description

Aim The aim is to test the hypothesis that a gel of either methylcellulose or psyllium incorporating inulin will reduce colonic gas volumes assessed by MRI 0-6 hours and 24 hours post ingestion as compared to inulin combined with placebo, maltodextrin.

Objective The primary objective is to define the effect of methylcellulose and /or psyllium on colonic gas as assessed by MRI. Previous studies have used large doses to ensure a large effect to avoid a type II error however the doses used are well outside the normal consumption. The investigators wish to compare the effect of the methylcellulose mix on the fermentation of 15 g of inulin.

Secondary Objectives A) Assess the effect of methylcellulose on gastric emptying, oro-cecal transit time (OCTT) by MRI assessment of arrival of "head of meal", regional MRI colonic appearances, including signal intensity at 6 and 24 hours to determine the likely length of effect, C) to asses breath hydrogen production over 24 hour post ingestion including overnight assessments, D) to assess Whole Gut Transit Time (WGTT) using blue muffins test, E) to measure AUC (0-24) for breath methane; F) to measure gas production over 48 hours incubation in vitro model of colon (in collaboration with Quadram Institute); G) to measure metabolite production (short chain fatty acids) using in vitro model of colon(in collaboration with Quadram Institute); H) to analyse microbiota using 16sRNA gene (in collaboration with Quadram Institute); I) to assess the effect of habitual dietary FODMAPs intake on breath hydrogen response to inulin.

Conditions

Colon, Irritable

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Psyllium

375 ml containing 15g inulin made up in 375 ml water with 15 g psyllium husk

Group Type: EXPERIMENTAL

Psyllium

Intervention Type: DIETARY_SUPPLEMENT

15 g psyllium + 15 g inulin

Inulin

Intervention Type: DIETARY_SUPPLEMENT

15 inulin

Methylcelulose

375 ml containing 15g inulin made up in 375 ml water with 15g modified methylcellulose

Group Type: EXPERIMENTAL

Methylcellulose

Intervention Type: DIETARY_SUPPLEMENT

15 g methylcellulose + 15 g inulin

Inulin

Intervention Type: DIETARY_SUPPLEMENT

15 inulin

Maltodextrin

375 ml containing 15g inulin made up in 375 ml water with maltodextrin powder (placebo)

Group Type: PLACEBO_COMPARATOR

Inulin

Intervention Type: DIETARY_SUPPLEMENT

15 inulin

Maltodextrin

Intervention Type: DIETARY_SUPPLEMENT

15 maltodextrin

Interventions

Psyllium

15 g psyllium + 15 g inulin

Intervention Type: DIETARY_SUPPLEMENT

Methylcellulose

15 g methylcellulose + 15 g inulin

Intervention Type: DIETARY_SUPPLEMENT

Inulin

15 inulin

Intervention Type: DIETARY_SUPPLEMENT

Maltodextrin

15 maltodextrin

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Able to give informed consent.
• Scoring ≤5 (i.e., mild, or less) for symptoms of flatulence, bloating, abdominal pain, loose stool, and hard stool in previous 2 weeks using a modified Gastrointestinal Symptom Rating Scale (5).
• Agrees to consume the meals provided.
• Agrees to not smoke during the breath hydrogen sampling period.

Exclusion Criteria

• • Pregnancy, lactating, or planning pregnancy during the course of the investigation declared by candidate.

• History declared by the candidate of pre-existing gastrointestinal disorder that may affect bowel function.
• Reported history of previous resection of the oesophagus, stomach, or intestine (excluding appendix).
• Intestinal stoma.
• Have contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury.
• Unable to lie flat and relatively still for less than 5 minutes.
• Any medical condition making participation potentially compromising participation in the study e.g., diabetes mellitus, respiratory disease limiting ability to use breath hydrogen analyser, known intolerance to one of the test substances.
• Has a body mass index (BMI) value less than 18.5 or greater than 35.
• Will not agree to follow dietary and lifestyle restrictions required.
• Participants who are taking antibiotics or probiotics as it might alters gut microbiota.
• Poor understanding of English language.
• Participation in night shift work the week prior to the study day. Night work is defined as working between midnight and 6.00 AM.
• Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g., cognitive dysfunction, chaotic lifestyle related to substance abuse.
• Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Quadram Institute Bioscience

OTHER

Sponsor Role: collaborator

University of Nottingham

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robin Spiller, MD

Role: PRINCIPAL_INVESTIGATOR

Professor

Locations

Nottingham Digestive Disease Centre

Nottingham, Nottinghamshire, United Kingdom

Countries

United Kingdom

Other Identifiers

FMHS 328-0723

Identifier Type: -

Identifier Source: org_study_id